New Search

If you are not happy with the results below please do another search

Search
Generic filters

50 search results for:

24

Cracking the code on social determinants of health: the essential role of market access

Many pharmaceutical companies listed strategic objectives for 2024 that included solving for health inequities, clearly positioned within pillars that focused on improving or increasing the value of their products. For one reason or another, many of those objectives were set aside as planning commenced in the new year, leaving this crushing challenge to our society unaddressed.

27

Amylyx plots new path in rare genetic disease after Relyvrio withdrawal

Amylyx Pharmaceuticals on Thursday released interim results from its ongoing Phase II HELIOS trial, showing that its lead asset AMX0035 (sodium phenylbutyrate and taurursodiol) improved pancreatic function and glycemic control in adult patients with the rare, inherited neurodegenerative disease Wolfram syndrome.